Results 201 to 210 of about 1,404,214 (346)

Pulmonary surfactant-biomimetic membranized coacervate injection for acute respiratory distress syndrome therapy. [PDF]

Acta Pharm Sin B
Chen W, Xie Q, Zhou Z, Kang J, Gao Y, Zhang H, Batur S, Fu C, Li Y, Yang C, Kong L, Zhang Z.   +11 more
europepmc   +1 more source

Alterations in Pulmonary Surfactant following Compression Atelectasis, Pulmonary Artery Ligation, and Reimplantation of the Lung

, 1967
Lazar J. Greenfield, Victor Chernick, W. Alan Hodson, GEORGE W. BRUMALEY   +3 more
openalex   +2 more sources

Response of Slowly Adapting Pulmonary Stretch Receptors in Surfactant Depleted Cat Lungs: Before and After Surfactant Replacement 226 [PDF]

, 1996
Richard Sindelar, V Dammann, Anders Jonzon, Peter Schaller, Andreas Schulze, Gunnar Sedin   +5 more
openalex   +1 more source

Shape affects the interactions of nanoparticles with pulmonary surfactant

Science China Materials, 2015
Xubo Lin, Y. Zuo, N. Gu
semanticscholar   +1 more source

A Unified Whole Lung PBK Model for Inhalational Uptake of Gases and Aerosols in Men

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Assessing the risk or benefit of an inhaled substance is challenging due to the variety of forms it can take (gas, vapor, particle, or droplet) and the complex biological processes involved in its uptake and retention. Physiologically based kinetic (PBK) models offer an alternative to in vivo experiments.
Norman Nowak, Sylvia E. Escher, Katharina Schwarz   +2 more
wiley   +1 more source

MR Imaging of Pulmonary Surfactant Distribution in a Preclinical Neonatal Lung Model. [PDF]

NMR Biomed
Marfouk O, Kaouane G, Leclerc L, Munsch F, Zhang B, Pinaud N, Gérard R, Fayon M, Périnel-Ragey S, de la Roque ED, Pourchez J, Crémillieux Y.   +11 more
europepmc   +1 more source

Retracted: ACE2 Promotes the Synthesis of Pulmonary Surfactant to Improve AT II Cell Injury via SIRT1/eNOS Pathway. [PDF]

Comput Math Methods Med, 2023
Methods In Medicine CAM.
europepmc   +1 more source

Prospective, Non-Blinded, Randomized Controlled Trial of Pulmonary Surfactant Administration Guided by Lung Ultrasound in Preterm Infants with Gestational Age < 32 Weeks [PDF]

Jinghui Zhang, Jinfang Yuan, Jing Xu, Tongyan Han, Yahui Zhang, Huiqiang Liu, Danfang Lu, Yunfeng Liu   +7 more
openalex   +1 more source

Engineering of pulmonary surfactant corona on inhaled nanoparticles to operate in the lung system

, 2023
Mojtaba Falahati, Anwarul Hasan, Hojjat Alizadeh Zeinabad, Vahid Serpooshan, Jan H. von der Thüsen, Timo L.M. ten Hagen   +5 more
openalex   +2 more sources

Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Nintedanib reduces the rate of decline in forced vital capacity (FVC) in adult patients with idiopathic pulmonary fibrosis (IPF), chronic progressive‐fibrosing interstitial lung diseases (ILDs) and systemic sclerosis‐associated ILD (SSc‐ILD).
Sonja Hartmann, Anna Chan Kwong, Jakob Ribbing, Martina Gahlemann, Julia Korell   +4 more
wiley   +1 more source